ReviewCancers2019

The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2- Metastatic Breast Cancer: Biological Mechanisms and New Treatments.

Daniele Presti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.